Lokelma label update approved in China for patients with hyperkalaemia on chronic haemodialysis


Deprecated: strlen(): Passing null to parameter #1 ($string) of type string is deprecated in /home/medicircle/public_html/script_newsdetails.php on line 75
▴ Lokelma label update approved in China for patients with hyperkalaemia on chronic haemodialysis
The NMPA has approved a dosing label update in China for AstraZeneca’s Lokelma to include patients with hyperkalaemia on chronic haemodialysis.

The National Medical Products Administration (NMPA) has approved a dosing label update in China for AstraZeneca’s Lokelma (sodium zirconium cyclosilicate) to include patients with hyperkalaemia on chronic haemodialysis.

The approval by the NMPA was based on data from the Phase IIIb DIALIZE trial, the first-ever randomised, placebo-controlled trial to evaluate a potassium binder in patients on stable haemodialysis. The trial showed sustained potassium control pre-dialysis for more patients receiving Lokelma, compared with placebo.

Lokelma was approved for the treatment of adult patients with hyperkalaemia in China by the NMPA in December 2019.

Mene Pangalos, Executive Vice President, BioPharmaceuticals R&D, said: “In China, more than 550,000 patients with chronic kidney disease on haemodialysis are at risk of developing hyperkalaemia, which can, in turn, lead to arrythmias and cardiac arrest. Today’s label update provides guidance to manage hyperkalaemia in this high-risk patient population, potentially enabling improved long-term treatment and overall kidney care.”

In DIALIZE, 41% of patients receiving Lokelma maintained pre-dialysis potassium levels on at least three out of four dialysis treatments after the long interdialytic interval and did not require urgent rescue therapy. This compared with 1% of patients receiving placebo, making it a statistically significant and clinically meaningful improvement (p<0.001). The safety profile of Lokelma observed in DIALIZE was consistent with previous trials.

Lokelma is a highly selective, oral potassium-removing agent currently approved in a number of markets across the globe including the US, China, EU and Japan for the treatment of hyperkalaemia.

Earlier this year, the US Food and Drug Administration (FDA) and the European Commission (EC) approved label updates in the US and EU, respectively, to include a dosing regimen specifically to treat hyperkalaemia in patients with end-stage renal disease on chronic haemodialysis.

Tags : #LatestPharmaNewsNov25 #LatestAstrazenecaNewsNov25 #TreatmentforHaemodialysis #TreatmentforHyperkalaemia

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Digital Identity Fraud in Healthcare: What India Must KnowNovember 18, 2026
Wearables in Clinical Care: When Should Doctors Trust the Data?November 18, 2026
Cybersecurity for Medical Startups: What Founders MissNovember 18, 2026
Remote Patient Monitoring: The Next Phase of Virtual CareNovember 18, 2026
Digital Health Wallets: Future of Medical Records in IndiaNovember 17, 2026
How Hospitals Can Prepare for a Transparent Healthcare MarketNovember 17, 2026
Childhood Nutrition: Understanding Micronutrient Gaps Beyond CaloriesNovember 16, 2026
Anaemia in Adolescent Girls: Connecting Prevention, Testing and Nutrition SupportNovember 16, 2026
Health Information Exchanges in India: Are Medical Records Finally Going Portable?November 16, 2026
Hospital Accreditation in 2026: What Is Changing Beyond the Checklist?November 16, 2026
Digital Insurance Platforms and India's Health Coverage FutureNovember 14, 2026
ABDM 2.0: India's Digital Health Ecosystem FutureNovember 14, 2026
Vaccine Cold-Chain Management: Protecting Immunisation Quality From Storage to DeliveryNovember 14, 2026
Foodborne Illness Surveillance: How Public Health Systems Track RisksNovember 14, 2026
Interoperability in Indian Healthcare: Why Patient Data Still StrugglesNovember 13, 2026
Tuberculosis Contact Screening: How Preventive Care Works Around ExposureNovember 13, 2026
COPD Care in India: Linking Diagnosis, Inhaler Education and Follow-UpNovember 13, 2026
Management of ANCA Glomerulonephritis: Induction & Maintenance ProtocolsNovember 12, 2026
Smart Hospital Command Centres Transforming IndiaNovember 12, 2026
Gamma Knife Surgery in India: What You Need to KnowNovember 12, 2026